Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.
Search results for: interstitial lung disease
A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.
Catch Your Breath: Insights into ILD in RA Patients
Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…
From the Expert: New Advances in Treatment of Systemic Scleroderma
A recent study found that mycophenolate mofetil is an effective alternative for the treatment of systemic scleroderma with interstitial lung disease, resulting in possible long-term improvement. According to Aryeh Fischer, MD, this new research points to the future expansion of treatment options…
Fellow’s Forum Case Report: Diagnosing Antisynthetase Syndrome
A variable combination of interstitial lung disease, myopathy, fever, joint involvement, and mechanic’s hands characterize this systemic autoimmune syndrome
Cilnidipine Receives Orphan Drug Status to Treat Systemic Sclerosis
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.
ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall
On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.
Through Thick & Thin: Updates in Scleroderma
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
Strong Argument: Recent Developments in Myositis Diagnosis & Care
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.
MCTD: Is It Just Letters?
At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 26
- Next Page »